HII
HII
NYSE · Aerospace & Defense

Huntington Ingalls Industrie

$324.48
+2.72 (+0.85%)
As of Aug 8, 9:41 PM ET ·
HII News15 articles
Navy Boosts Seabed Contract to $24.8M, Near $25M Cap
The U.S. Navy exercised a $9.8 million option on a seabed contract with Integer Technologies and the University of Southern Mississippi, bringing the total to $24.8 million—99.2% of the $25 million cap. The award fuels demand for autonomous underwater software.
Markets
Boring Company Seeks $4 Billion at 200x Sales Valuation
The Boring Company is raising $4 billion at a proposed $20 billion valuation, a 3.5x increase from 2022, with a sales multiple over 200x.
Markets
JPMorgan Backs $2.5B Shipbuilding Deal, Aims to Boost Maritime Sector
JPMorgan Chase (JPM) is providing $24 million in funding for a $2.5 billion shipbuilding deal between Rhoads Industries and Electric Boat, a General Dynamics subsidiary.
Markets
Defense Stocks Rally Ahead of Holiday; AST SpaceMobile Unveils $1B Financing
U.S. defense and space equities advanced Friday, led by Lockheed Martin and Huntington Ingalls, while AST SpaceMobile announced a major $1 billion financing initiative. Markets are closed Monday for the Presidents Day holiday.
Markets
Huntington's Valuation Gap Widens as Q4 Synergy Deadline Looms
Huntington Bancshares (HBAN) closed at $17.60, up 0.2%, but trades at a 14% tangible-book discount to peers. Q4 synergy execution is now the key catalyst.
Earnings
Huntington Bancshares Falls on Weak Interest Income, Merger Doubts
Huntington Bancshares shares fell 1.1% after net interest income missed expectations, leading to a Bank of America downgrade and raising questions about merger benefits.
Markets
Huntington Bancshares Declines 4.9% as Rising Deposit Costs Pressure Margins
Huntington Bancshares (NASDAQ:HBAN) shares dropped 4.9% this week as rising deposit costs and a declining net interest margin overshadowed solid fee income growth.
Earnings
Huntington Bancshares Slips 5% on Deposit Cost Pressure Despite Strong Organic Growth
Huntington Bancshares shares dropped 5.1% on Thursday as rising deposit costs and a declining net interest margin overshadowed strong organic deposit growth.
Markets
Huntington Bancshares Q2 Preview: Deal-Driven Growth Meets EPS Expectations
Huntington Bancshares (HBAN) closes up 0.6% ahead of Q2 earnings, with analysts eyeing deal-driven EPS growth amid integration costs and margin pressures.
Earnings
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
Markets
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
Regulation
Huntington Bancshares Surges on Heavy Volume, Regional Banking Outlook Brightens
Huntington Bancshares jumped 1.49% on double-average volume, outperforming regional peers. Q1 net income hit $523M, adjusted EPS 37¢, and Cadence Bank integration wraps in Q2. Management to present at Morgan Stanley June 9.
Markets
Huntington Bancshares Reaffirms 2026 Outlook Amid Stock Consolidation
Huntington Bancshares shares stabilized around $15.50 as management confirmed its 2026 financial guidance and projected $550 million in stock buybacks for that year, while anticipating significant cost savings from recent acquisitions.
Markets
Huntington Bancshares Shares Rebound on 2027 EPS Outlook and Merger Synergy Details
Huntington Bancshares stock rose 0.5% Wednesday, recovering from a prior sell-off, as investors assessed its 2027 EPS target of $1.90-$1.93 and $435M in projected annual cost synergies from recent acquisitions.
Markets
Huntington Bank Appoints Former BNY Risk Chief as CRO Amid Regulatory Shift
Huntington Bank has named Senthil Kumar, previously the top risk officer at BNY, as its new chief risk officer. The move follows the bank's entry into a stricter regulatory category after its merger with Cadence Bank pushed assets to $279 billion.
Regulation